Abstract
Aim: Clinical use of Recombinant Human Erythropoietin (rHuEPO) effectively increases the level of Hemoglobin in blood and improve quality of life of patients. Methods: Blood cancer patients is divided into two groups namely Treatment group and Control group. There is altogether 24 patients in treatment gp to whom both chemotherapy and rHuEPO is given for 4 weeks. rHuEPO is given as 150u/kg，subcutaneously, three times a week. Blood routine check up is done in every week and iron is prescribed after 2 weeks. Result: After 4 weeks of treatment, patients were evaluated for drugs effectiveness in both groups; total effectiveness were 58.34% and 20% respectively, P >0.05; after 4 weeks of treatment, there was distinct statistical significance. Comparing with pretreatment level, Treatment group has remarkable rise in Hb after 4 weeks (81.29±9.85)对（65.75±12.37），（P<0.01, whereas control group has not distinct change in Hb level(86.95±11.61)对（84.30±16.25），（P>0.05. Conclusion: Hb is significantly increased after the use of rHuEPO and side effects were less with well tolerances.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Medical Science and Clinical Invention
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
